Indraprastha Medical
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Indraprastha Medical Corporation Limited (IMCL) is positioned to leverage its integrated healthcare services in India, with management emphasizing clinical excellence and diversification into high-acuity segments such as oncology and cardiac care. This strategic focus is expected to enhance average revenue per patient (ARPP) and support stable revenue growth, aligning with Vista's forecast of consistent historical performance. Additionally, IMCL's commitment to digital innovation and cost optimization is crucial in navigating rising operational costs, which could otherwise pressure margins. The company's proactive approach to expanding capacity and achieving international accreditation standards further strengthens its competitive position. While the healthcare sector is experiencing a mixed outlook due to projected declines in EBITDA margins and regulatory challenges, the overall demand for organized healthcare services remains robust. Vista's financial outlook reflects these dynamics, with expected revenue growth and stable margins, supported by a fair valuation and an anticipated upside of approximately 12.38%. Over the next 12-24 months, key opportunities include the rising demand for corporate healthcare and improved access through insurance coverage, while headwinds may arise from competitive pressures and regulatory compliance challenges
Why We Like This Stock
- Management's focus on high-acuity segments like oncology and cardiac care is expected to enhance revenue per patient
- Digital innovation and cost optimization strategies are being implemented to mitigate rising operational costs
- The demand for organized healthcare services is increasing, supported by rising insurance coverage
Things To Watch Out For
- Projected declines in EBITDA margins could impact overall profitability
- Competitive pressures and regulatory compliance pose risks to operational efficiency
- Economic inflation and currency dynamics may temper consumer spending in healthcare
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,245 | 1,356 | 1,483 | 1,523 | 1,676 |
| Profit Before Tax (Cr.) | 167 | 217 | 246 | 247 | 274 |
| PBT Margin | 13.4% | 16.0% | 16.6% | 16.2% | 16.3% |
| Net Profit (Cr.) | 124 | 157 | 189 | 190 | 210 |
| Earnings Per Share | 13.5 | 17.1 | 20.6 | 20.7 | 22.9 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.